<DOC>
	<DOCNO>NCT00271427</DOCNO>
	<brief_summary>Selenium suppress autoimmune destruction thyrocytes decrease titer serum TPOAb AIT patient . Older 4 clinical trial approve efficacy daily dose 200micg . It 's believe Se saturate deficient store GPX GPX save thyrocytes oxidative stress . Although less 70 micg/d sufficient maximize GPX activity , none author test dos less 200 micg/d . Our hypothesis If 100 micg/d suppress TPOAb titer , mean autoimmune destruction block saturation deficient store GPX solely mechanism action require repletion deficient store . It 's important estimate optimal dose understand mechanism action . High dose therapy may also suppress TPOAb level Se-non-deficient AIT patient , , Se therapy may become solely treatment modality suppress autoimmunity 400 million AIT patient . Because 've way suppress autoimmune war replacement LT4 treatment modality palliation . An independent part study test effect Se adolescent AIT patient .</brief_summary>
	<brief_title>Selenium Treatment Autoimmune Thyroiditis ( AIT )</brief_title>
	<detailed_description />
	<mesh_term>Thyroiditis</mesh_term>
	<mesh_term>Hashimoto Disease</mesh_term>
	<mesh_term>Thyroiditis , Autoimmune</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>Clinically approve AIT patient use medication LT4 keep TSH low half normal range . Any kind drug use LT4 kind know pathology may effect GIS absorption .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>Thyroiditis</keyword>
	<keyword>Autoimmune</keyword>
	<keyword>Hashimoto 's</keyword>
	<keyword>TPOAb</keyword>
	<keyword>Selenium</keyword>
</DOC>